Craig Wheeler, Momenta CEO (Michael Fein, Bloomberg via Getty Images)
Momenta clears a PhII hurdle on nipo — but one big rival remains well in the lead in this packed field
Momenta $MNTA had a few things to prove going into its interim analysis of a Phase II study for its drug nipocalimab (M281) in treating …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
